News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

VinBrain becomes NVIDIA Inception Premier Member

Vingroup

HANOI, VIETNAM - Media OutReach - 14 March 2023 - VinBrain has become a Premier member of NVIDIA Inception, a global program that provides cutting-edge startups with access to accelerated computing resources and more. By teaming up with NVIDIA, VinBrain is poised to transform HealthTech innovation in Southeast Asia, building on its previous successful collaborations with Microsoft and Stanford University. As a Premier member of NVIDIA Inception, VinBrain has the advantage of being an early adopter of NVIDIA's latest hardware innovations. Moreover, VinBrain receives ongoing technical support by regularly meeting with R&D experts, empowering the company to design and train advanced AI models and seamlessly integrate AI systems into clinical workflows. With this capability, VinBrain is better equipped to serve hundreds of hospitals across Vietnam, the United States, and Southeast Asian nations with optimal efficiency. VinBrain's AI product suite, including DrAid™, AIScaler™, and SenMe™ (aka AIviCare™) is now featured on the NVIDIA Accelerated Apps Catalog. “ We are thrilled to become a Premier member of NVIDIA Inception,” said Steven Truong, CEO of VinBrain. “ VinBrain has collaborated with Microsoft Corporation on data sharing, cross-validation, product research and development, and with Stanford University on in-depth research and data use, including hundreds of thousands of shared medical images. Continuing collaboration with NVIDIA in the hardware field will create a strong foundation for VinBrain to enhance quality, efficiency, and accessibility of healthcare services, bringing the best value of AI to provide effective support for patients and doctors." VinBrain has committed to NVIDIA's cutting-edge tech solutions from the outset, relying on the NVIDIA Clara healthcare platform, MONAI open-source framework, and NVIDIA NeMo framework for training, customizing and deploying generative AI models. Likewise, VinBrain has used NVIDIA DGX SuperPOD-powered AI supercomputing to develop computer vision solutions for medical imaging, intelligent video analytics, automatic speech recognition, natural language processing, and text-to-speech, resulting in 100x faster model training than with CPU only. “ VinBrain provides impactful solutions for many hospitals globally and supports healthcare professionals to augment their workflows and deliver precision radiology,” said Renee Yao, Global Healthcare AI Startups Lead at NVIDIA. “As a Premier member of NVIDIA Inception, VinBrain will work with NVIDIA to improve healthcare and precision medicine.” Healthcare has notably been one of the emerging industries in NVIDIA’s Inception, which now boasts over 1,300 healthcare startups. Steven Truong will speak at an exclusive Healthcare AI Council as part of NVIDIA GTC, a global AI conference running March 20-23, 2023 in San Francisco, US. He will share his thoughts on the future of innovation in the healthcare and life sciences industry and discuss how to collaborate globally and bring bigger impacts to improve patient outcomes and efficiency for doctors’ workflows. About VinBrain As a 4-year-old startup, Invested by Vingroup, the biggest conglomerate in Vietnam, VinBrain has a mission to infuse AI and IoT to improve people's lives and productivity. The company has developed over 300 AI models that process medical images and medical reports including X-ray, CT, MRI and medical reports data from a dataset of over 2.5 million images and big data of text. The comprehensive AI platform, DrAid™, has been deployed in over 100 hospitals in Vietnam, Myanmar, New Zealand, and the US.To learn more, visit the VinBrain website: https://vinbrain.net/ Contact Details Media Contact v.chidqd1@vingroup.net Company Website https://vinbrain.net/

March 14, 2023 09:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

New Policy to Allocate Donor Lungs Takes Effect

United Network for Organ Sharing

Earlier this month, United Network for Organ Sharing (UNOS) launched a new lung allocation policy that will increase equitable access for patients who are in greatest need of a lung transplant while decreasing the overall number of patient deaths on the national waitlist. UNOS is the non-profit that contracts with the federal government to serve as the nation’s Organ Procurement and Transplantation Network (OPTN). Developed with the help of the Massachusetts Institute of Technology (MIT), RTI International (RTI) and the Scientific Registry of Transplant Recipients (SRTR), this policy is the first to use continuous distribution, which will become the standard for kidneys, pancreases, hearts, livers and other types of organ transplants in the future. This new, dynamic framework relies on a more holistic view of each patient, dissolves rigid boundaries that exist in the current, category-based system, and ensures that no single factor determines a patient’s priority on the waitlist. Donor lungs will now be allocated based on a unique composite score developed for each patient. This score will be based on a variety of factors, including illness severity, biology, expected time of life after transplant and more. “This innovative new system will be more equitable and patient-focused,” said Marie Budev, D.O., M.P.H., who serves as chair of the OPTN Lung Transplantation Committee, which spearheaded the policy development. “Instead of considering the many factors that define a candidate's unique need for an organ sequentially, we can now consider them all simultaneously for each patient.” Researchers from MIT's Sloan School of Management assisted the committee in developing the continuous distribution framework by applying artificial intelligence (AI) and machine learning to evaluate the effectiveness of millions of different policy scenario options. RTI contributed analysis, and the SRTR performed simulation modeling to validate results, remaining involved throughout the policy framework’s implementation. “Continuous distribution is a generational change in the field of organ allocation,” said James Alcorn, senior policy strategist at UNOS. “We were able to build a system that’s much nimbler than before, allowing us to identify issues and implement solutions much more quickly in the future.” As part of the policy development process, a diverse group of nearly 200 individuals representing a wide range of experiences and perspectives in donation and transplant, including patients, took part in an exercise where they shared what factors they considered most important when developing the composite score. Similar to how one turns a dial, the committee can now easily adjust the weights on the scale to further optimize the allocation system when policy changes are approved. “Take pediatric priority, for example. When we identify a certain patient group that is not appropriately prioritized, we can quickly identify the attribute they share in the system, and then adjust its weight to improve the entire system,” Alcorn said. Statistical modeling predicts that the new lung policy will not only reduce the number of patients who die waiting for a lung transplant but will also increase access to transplants for patients in need, including those with the most severe illness. A recent study by the Cleveland Clinic, in partnership with the SRTR, found that across all modeling scenarios, “the system led to improved overall measures of equity” when compared to the previous system. UNOS has hosted multiple webinars and provided resources to support patients, physicians and other donation and transplant professionals during the transitional phase. To date, hundreds of individuals have attended these public webinars. Additionally, UNOS has created patient materials that address questions for candidates on the waiting list. The OPTN Board of Directors unanimously approved the policy in December 2021. The OPTN Lung Transplantation Committee will actively monitor the new lung policy and, if needed, make recommendations for additional improvements. Work to transition all other organ types to the continuous distribution framework is proceeding, with kidney and pancreas policies anticipated next. About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

March 14, 2023 09:17 AM Eastern Daylight Time

Video
Article thumbnail News Release

Futura Medical expects FDA approval for topical ED treatment during Q2

Futura Medical PLC

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Proactive's Thomas Warner after announcing the European online launch of topical erectile dysfunction (ED) treatment MED3000, under the brand name Eroxon. Barder also gives an update on the company's discussions with the FDA regarding MED3000, saying that he expects approval to come during the second quarter. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 14, 2023 09:02 AM Eastern Daylight Time

Video
Article thumbnail News Release

Ozempic Weight Loss: Newly Launch Over The Counter Alternatives To Ozempic & Semaglutide For Weight Loss

Allied PR

Are you seeking dietary remedies to help you lose excess body fat? Extra body fat-related issues are becoming more widespread as a result of everyone consuming unhealthy foods and failing to take care of their health. People work at desk jobs and do not move their bodies, which causes stiffness and attracts a slew of obesity-related issues. All of your activities and poor eating habits contribute to obesity, which attracts a slew of associated health conditions. To do this, you must avoid all of these issues and maintain a healthy body shape as soon as possible. Click here to buy alternative to Ozempic OTC such as PhenQ. New Ozempic Weight Loss Alternatives on the Market PhenQ PhenGold TrimTone LeanBean PrimeShred You may consume healthy foods and engage in regular physical exercises. If your body isn't cooperating or you can't stick to your tight diet, don't worry because the article has you covered with the best Ozempic Weight Loss Alternatives. You may select any of the supplements listed below since they all employ an effective formula to function and will only deliver many advantages to everyone who drinks them on a regular basis. These are from respectable backgrounds, and you may totally trust them. 1. PhenQ ~ Fat Burner, Fat Blocker and Appetite Suppressant PhenQ is a nutritious weight reduction product that works exclusively in the most efficient manner for everyone. This weight reduction solution has various advantages and may be completely trusted. This supplement decreases cravings and may also target all the accumulated fat that your body has accumulated in various body areas such as the neck, thigh, and so on. It may assist you in achieving your ideal body shape in a short period of time while allowing you to do your daily tasks without a problem. It aids in the natural loss of extra body fat. You will not have any problems. You may be certain that it works and that you can consume it on a regular basis if you desire to see positive outcomes. It will also help you stick to a rigorous diet and might even give you the drive to finish it without quitting in the middle. (ACT NOW & SAVE) Click Here to GET PhenQ From The Official Website Ingredients: PhenQ contains caffeine, capsimax powder, nopal, L-carnitine, chromium picolinate, and alpha lacy's reset. The substances will only benefit you as they are all pure and natural. It is high in proteins and will offer you several advantages if consumed on a daily basis. All of these substances have unique advantages. This is the reason to manufacture this effective formula that can curb your appetite without causing any problems. Benefits: If we talk about the massive advantages that are associated with the PhenQ weight loss formula and that you can receive if you consume the supplement on a daily basis. They include: subduing the unwelcome cravings that cause you to gain unwanted body fat, increasing your level of energy so that that you can be physically active and exercise without needing anyone's assistance, improving your immunity levels, blocking excess fat so that the body is not able to store fat in tough areas. 2. PhenGold PhenGold is a weight reduction supplement that is both effective and nutritious for everyone. Many weight-related issues are tenacious, and many individuals are dealing with them. They are unable to get rid of excess body fat, which is why you may use this product to get rid of accumulated fat. The supplement will not cause you any trouble and will solely function for your benefit. There is a comprehensive list of the several advantages that the supplement delivers. Click Here to PhenGold For The Lowest Price Right Now Ingredients: When it comes to the various ingredients that are involved in the makeup of the PhenGold weight loss pill, only nutritious ingredients are blended in its dose. Since it has been created in labs, this is among the most nutritious supplements available. Green tea extracts, L-Tyrosine, green coffee extracts, L-theanine, Rhodiola Rosea, DMAE l, cayenne pepper, and other substances may be present. Apart from these, vitamin B3, Vitamin B6, and Vitamin B12 are also present, making it beneficial for everyone. Benefits: When it comes to the many benefits linked with this weight reduction formula, the supplement solely works for your benefit. This Ozempic Weight Loss Alternative has numerous benefits to offer each of its customers, and it works by improving focus levels and mood, increasing your motivation levels, increasing your ability to burn fat in a short period of time, boosting your metabolic rate, suppressing your appetite, removing brain fogging, assisting you in improving your overall cognitive functioning, and so on. 3. Trimtone ~ Best Fat Burner For Women Trimtone is a 100% natural and powerful fat-burning supplement geared specifically towards women. It may aid in weight loss by increasing thermogenesis and metabolism. This product promises to burn hard-to-move fat and turn it into energy. This enables the person to go through the day without feeling weary, even while following a low-calorie diet and without sacrificing the outcomes. The medication may also help to reduce appetite and urges, making it simpler to resist snacking and ultimately eat less. This weight loss vitamin is undeniably helpful in achieving weight reduction and fitness objectives. This, however, will happen slowly. To get the most advantages, use this supplement in combination with a healthy weight reduction diet and activity routine. Ingredients: Trimtone is made up of five key natural components, as well as those needed for the pill and to promote consistency and quality control. Trimtone is not suitable for vegans or vegetarians since the capsules contain gelatin. The following components and their functions are listed: Caffeine Anhydrous Extract of Green Tea Glucomannan Green Coffee Grains of Paradise Benefits More strength: Trimtone, which includes a modest amount of caffeine, boosts the production of oxygen-rich red blood cells while simultaneously providing an energy boost. Since the body cannot burn fat in the absence of oxygen, the presence of an increased quantity of red blood cells means that the body will work at a higher level, making it easier for nutrients to be used aerobically for longer periods of time. Fat-Burning: Fat reduction may be accomplished by combining a faster metabolism, thermogenesis, and consuming less calories. The body will consume more calories than it eats, with the excess energy coming from stored fat. This is known as fat oxidation. Reduces appetite: A key component of reducing weight is eating less calories. It is hard to lose weight unless one consumes less calories than expended by the body. Trimtone includes ingredients that help you feel fuller with less calories, lowering your total calorie intake all day and aiding with fat reduction. Increases metabolism: The quicker the metabolism, the more calories are burnt by the body. Trimtone's components have been shown to increase metabolism. 4. LeanBean LeanBean is a rapid weight loss product that aids in the natural elimination of any superfluous body components. This Ozempic Weight Loss Alternative is healthy and beneficial to your health. It has several components that may help by activating your fat-burning skills and improving your metabolic rate. It also makes it extremely easy to enter ketosis and operates in a natural manner for everyone who drinks it on a regular basis. This weight loss supplement's manufacturer has only assured that it would deliver long-term advantages to everyone. Ingredients: Choline, Green coffee extracts, Glucomannan, Vitamin B12, vitamin B6, zinc, and other ingredients are included in the dose of the weight reduction formula. This supplement is made with only natural components; therefore it will not hurt anyone's health. You may use this product on a regular basis, and it will only benefit you. You can rely on it. Because of the pure substances used in the formulation of this weight reduction recipe, it works well. Benefits: The numerous advantages that LeanBean offers to everyone who consumes it consistently include: reducing sugar cravings, initiating fat-burning abilities, sustaining healthy body fat, reducing obesity effectiveness, supplying a large amount of nutrients to your entire system, maintaining healthy body weight, and so on. 5. Prime Shred ~ Best Fat Burner For Men Prime Shred is a powerful weight reduction supplement. It is a powerful composition that only gives many advantages to those who use it on a regular basis. Prime Shred is devoid of toxins and may offer users a variety of advantages. This supplement was created by a team of experts that conducted an extensive study on how to create weight loss pills that only include elements that may activate your body's metabolism and assist you in entering ketosis. The manufacturers have conducted a study on how a person's body weight functions and what variables are accountable for gaining undesired body fat in a short period of time. You will not have any problems if you consume it on a regular basis. The firm that supplies this supplement also offers a variety of policies to all customers. You might get substantial discounts if you purchase the supplement in bulk. Furthermore, it contains only non-GMO components and is vegan-friendly. PrimeShred is devoid of chemicals and may assist you in a variety of ways rather than harming you in any manner. Ingredients: Cayenne pepper, amino acids, L-Tyrosine, extracts of green tea, l-theanine, green coffee extracts, and other ingredients are included in the formula. All of this serves to boost your body's energy and might even help you get into shape faster. These may not be harmful to anyone's health and may merely supply you with several advantages. Benefits: The numerous positive effects that Prime Shred weight loss formula has to offer each of its customers include: helping you burn fat in a very short period of time so that you do not struggle to get rid of your excess calories, reducing fat storage, reducing sugar cravings, boosting your energy levels to a new level, improving your mood, allowing you to remain fit and happy all through the day, improving your mental functioning, and so on. Click to view pricing on cheaper alternatives to Ozempic in stock About Ozempic Those who have type 2 diabetes get the medication Ozempic as a weekly injection. This treatment is administered subcutaneously. This therapy is intended to assist in better managing the blood sugar in the body, which is the purpose of the treatment. And although Ozempic is not generally acknowledged as a medicine for losing weight, there is some data that suggests that persons who use the medication may experience a small amount of weight reduction. This is the case even if Ozempic is not officially recognized as a treatment for weight loss. The fact that this is the case persists despite the fact that Ozempic is not a drug for weight reduction. In spite of the fact that Ozempic is not often thought of as a prescription medication for weight loss, this is, in fact, the case. Insulin and Ozempic are in no manner, shape, or form similar to one another in any way. When there is a high concentration of glucose in the blood, Ozempic acts as a pancreatic stimulant, which in turn causes the pancreas to generate a greater quantity of insulin. This impact is nullified if there is a very small quantity of sugar present in the blood. In stark contrast to insulin, the administration of Ozempic is only associated with hypoglycemia in patients under the most extreme of situations. Even though Ozempic is in no way marketed as a prescription for weight loss in any way, the manufacturing business warns buyers that semaglutide, which is the main ingredient of the drug, could cause users to feel a reduction in body mass. This warning is given despite the fact that Ozempic is not introduced to the market as a prescribed medication for weight loss in any way. Although Ozempic is not marketed as a prescription medication for weight reduction, this situation has arisen as a result of using the product. Individuals will be permitted to use this drug for the goal of reducing their body weight after receiving approval to do so. The weight loss medication semaglutide not only amplifies the benefits of the naturally occurring hormone GLP-1 but also exerts its impact on weight regulation via two key pathways. These channels are to blame for the following effects that the medication has on the body: Affects the areas of the brain responsible for hunger (especially the hypothalamus), which leads to a reduction in appetite, hunger, and cravings. By slowing the rate at which the stomach empties after meals, this supplement effectively prolongs the feeling of fullness and satiation that follows eating. The final result is a diminished sense of hunger, maintained fullness, and a loss of excess weight. Conclusion: Ozempic Weight Loss To sum everything up, the only thing that can be stated is that individuals should never, ever neglect the challenges that their bodies are going through. This is the advice that tops the list as the most crucial that can be given. Because the body is very important, nothing in the world, riches or anything else, will be able to aid it if it cannot take care of itself in later years. Because of this, it is imperative that an individual makes an attempt to take good care of themselves and treat any and all difficulties related to obesity since the disease may lead to a variety of other health conditions that represent a danger to one's life. The new top alternative to Ozempic's weight reduction program is discussed in the section of this article that came before the one you are now reading. Simply deciding to go with one of these courses of action is all that is required to find a solution to the myriad of issues that are associated with obesity. Disclaimer: This article is provided by an advertiser. Statements made are not meant to offer medical advice or to diagnose any condition. Any studies cited here may be preliminary, and may or may not be peer-reviewed, and may or may not have sufficient participants to be statistically relevant. Products discussed in this article are not designed to diagnose, treat, prevent, or cure any disease. The FDA does not evaluate dietary supplements. Consult your doctor about possible interactions, allergies, and if you are considering using natural and/or dietary supplements for any condition. Individual results will vary. Contact Details Melissa support@jollofnews.com

March 14, 2023 01:06 AM Eastern Daylight Time

Article thumbnail News Release

DSS Inc (NYSE American: DSS) Has Three IPO Spinoffs Planned For 2023 — Is It On Your Watchlist?

DSS, Inc.

By Ernest Dela Aglanu, Benzinga Since 2019 when DSS Inc. (NYSE American: DSS) embarked on a major transformation journey, the company has evolved into a multinational company operating businesses in nine divisions with over 40 subsidiaries. Headquartered in New York, the company has developed strong market positions in product packaging, biotechnology, direct marketing, commercial lending, securities, and investment management, alternative trading, digital transformation, secure living, and alternative energy. These nine divisions and 40 subsidiaries offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers but also create sustainable value and opportunity for transformation and value creation A study of the company’s website and investor deck reveals growth in diverse market sectors which is being fueled by an “incubator” strategy of acquiring and developing assets to enhance shareholder value through calculated IPO spinoffs and a parametric share distribution strategy.(??) A Closer Look At DSS’s Financials This strategy appears to be having a positive impact on DSS’s financials. A due diligence dive into the company’s financials show that the company’s total Net Asset Value (NAV) as of September 30 last year was $182.6 million, or $1.31 NAV per Share. Third Quarter 2022 revenues ballooned astronomically by 172% Quarter to Quarter, total assets were valued at $264 million, up significantly from the $20 million in assets as of December 2019. As of March 10th, 2023, DSS’s Market Cap was $33.5 million ($0.24/share) meaning shares are trading at approximately an 80% discount from September 30th’s NAV per share of $1.31. The company’s revenue for Q3 2022 was more than $35.9 million, compared to $13.2 million in the same quarter of 2021, representing a 170% increase. Market Potential Could Be Massive DSS believes that the markets the company operates in have nearly unlimited potential, and the opportunities within multiple high-growth markets are endless, predominantly because entities within these sectors are contemporary, scalable, and offer recurring revenue streams. Product packaging is projected to surpass $1.3 trillion in market size by 2028. The biotechnology market is expected to be worth around $3.44 trillion by 2030. Direct Marketing is a global business generating approximately $180 billion and is projected to have its fifth year of double-digit growth in 2023 spurred by the new Gig Economy. Commercial Lending Growth was at a 14-Year High in 2022, and the market size valued at over $8 billion in 2020 is projected to reach almost $30 billion by 2030. Securities is a high-growth sector of $70 trillion, and REITs earnings increased 24.6% this past year. DSS certainly seems to be following a focused strategy to continue to create shareholder value. The company says it achieves this by focusing on key areas for growth, such as developing solid revenue growth, increasing profitability, and growing assets that drive stock price and market cap. Buying Assets - Securing businesses and infrastructure to generate revenue. Business Optimization - Identifying business needs, providing financial resources, and empowering and incentivizing the management teams of the subsidiary businesses to be successful. Positive EBITDA - Achieving positive earnings before interest, taxes, depreciation, and amortization (EBITDA) by creating economies of scale and revenue generation within those businesses. Public Offerings - Sharing success with existing and new shareholders through the periodic distribution of stock dividends as subsidiary spinoffs through an Initial Public Offering (IPO). Monetizing Growth In Key Sectors DSS is acquiring ownership positions or fully acquiring businesses in high-growth sectors to monetize its holdings. The company reports that by transitioning its revenue streams into exponential and emerging new business lines, operating the business to create growth opportunities and scalable and recurring revenue, and restructuring and developing assets to position them for growth and potential monetization, DSS will eventually be creating more shareholder value. With companies like Johnson & Johnson (NYSE: JNJ), General Electric Company (NYSE: GE), and 3M Co. (NYSE: MMM) recently making headlines due to spinoff opportunities for shareholders, one of the most unique aspects of DSS for investors could be its strategy of incubation and subsequent spinoff of companies under its wing, automatically providing investors with pure-play tickers just by owning shares of DSS. This article was originally published on Benzinga here. DSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors. These companies offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers, but also create sustainable value and opportunity for transformation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details Rick Lutz- TraDigital IR rick@tradigitalir.com Company Website https://www.dssworld.com/

March 13, 2023 09:25 AM Eastern Daylight Time

Article thumbnail News Release

The LED Lighting Market’s Growth Is In Double Digit Rates And Order Books Are Growing – Applied UV (NASDAQ: AUVI) Sub Just Secured A Multi-Million Order From A Leading Luxury Developer

Applied UV, Inc.

By Ernest Dela Aglanu, Benzinga The global LED lighting market, thanks to players like Applied UV Inc. (NASDAQ: AUVI), is witnessing significant growth. The market size was valued at $68.9 billion in 2022 and is projected to reach $264.08 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 17.6% during the forecast period. One of the primary drivers of the market’s growth is the rising need for energy-efficient light sources. LED lights consume less energy and have a longer lifespan compared to traditional lighting sources such as incandescent bulbs, fluorescent tubes, and halogen lamps. As a result, LED lights are gaining popularity in both the residential and commercial sectors, leading to a surge in demand. Additionally, increasing environmental awareness and conscious efforts toward sustainability are also contributing to the growth of the LED lighting market. LED lights are free from toxic materials such as mercury that pose a threat to the environment and human health. Therefore, they are considered eco-friendly and have become the preferred choice for lighting solutions in many sectors. Governments worldwide are implementing favorable policies to encourage the adoption of LED lighting. In many countries, subsidies, incentives, and tax benefits are offered to consumers who opt for LED lights. These government initiatives have resulted in increased awareness and adoption of LED lights, further fueling the market’s growth. The increasing LED lighting adoption and growth of the market is good news for companies like Applied UV, Universal Display Corporation (NASDAQ: OLED), Energy Focus Inc. (NASDAQ: EFOI), and LSI Industries Inc. (NASDAQ: LYTS) that are developing products to meet growing demand. Within the industry, Applied UV seems to have carved a niche for itself as a provider of proprietary surface and air disinfection technology focused on Improving Indoor Air Quality (IAQ), specialty LED lighting, luxury mirrors and commercial furnishings – all of which serves clients globally in both the commercial and retail segments. The company’s products address needs in the healthcare, hospitality, food preservation, cannabis, education, and winery vertical markets. Applied UV has established strategic manufacturing partnerships and alliances, including Canon, Acuity, Johnson Controls, USHIO, Siemens, Grainger, and a global network of 64 dealers and distributors in 52 countries, offering a complete suite of products through its two wholly owned subsidiaries — SteriLumen Inc. and MunnWorks LLC. Multi-Million Dollar Order From Premier Developer Applied UV ’s growth and recent announcement of purchase orders totaling $4.55 million could interest investors and watchers of the LED lighting industry. The company recently revealed that its wholly owned subsidiary LED Supply Co. had secured a multi-million dollar purchase agreement from an unnamed premier co-living rental property developer The X Company (“X Co.”). The purchase orders consist of $2.67 million received and the balance of $1.88 million assured by the end of the second quarter. LED Supply Co. will provide back-lit mirrors, LED lighting and control systems for X Co.’s growing billion-dollar portfolio of properties. The orders will be fulfilled by LED Supply Co., in partnership with MunnWorks, who will manufacture the backlit mirrors in its newly acquired 100,000-square-foot Brooklyn, NY facility. “Having access to the MunnWorks’ high-end U.S.-made decorative backlit mirrors and case goods, at competitive prices, allows us to provide a better-quality product to our residents while staying within our allotted budget on a project,” Ben Brichta, Partner at X Co., said. The premier co-living rental property developer reports that it is active in six markets, with 5,000 beds in its current portfolio and over $1 billion in construction activity. The company says it is fully integrated — able to acquire, design, build and operate its real estate assets. X Co. buildings offer a high level of amenities and resident experiences in their unique combination of private rentals, co-living suites and co-working spaces. They also offer residents an unconventional club environment supporting the growing work-from-home segment with a state-of-the-art gym and fitness studios, social activities and dramatic shared spaces. The orders more than double X Co.’s previous orders with LED Supply Co. and expands them to include backlit mirrors supplied by Applied UV subsidiary MunnWorks, with subsequent orders planned for later this year. The joint order is the first in what the company expects to be many collaborative sales efforts forecasted as part of the merger of Applied UV, LED Supply Co. and PURO Lighting announced in January of this year. This article was originally published on Benzinga here. Applied UV is focused on the development and acquisition of technology that addresses infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Airocide® air purification devices are research-backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors, and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine-making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities, and homes. SteriLumen’s connected platform for Data-Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen-intensive location. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Brett Maas- Hayden IR brett@haydenir.com Company Website https://www.applieduvinc.com/

March 13, 2023 09:15 AM Eastern Daylight Time

Article thumbnail News Release

Redx Pharma sees potential for RXC004 as a combination therapy

Redx Pharma PLC

Redx Pharma PLC (AIM:REDX) chief medical officer Dr Jane Robertson speaks to Proactive's Thomas Warner after announcing that phase II data from the first group of patients being administered RXC004 for biliary tract cancer was not enough to support further development. Robertson highlights RXC004's potential for use as a combination therapy. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 13, 2023 08:32 AM Eastern Daylight Time

Video
Article thumbnail News Release

Headline

Creo Medical Group PLC

Proactive research analyst Daniel Appiah speaks to Thomas Warner after publishing a new report on Creo Medical Group PLC (AIM:CREO) that follows a £33.7mln fundraise. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 13, 2023 08:28 AM Eastern Daylight Time

Video
Article thumbnail News Release

MGC Pharmaceuticals "totally understands" CimetrA after MoA study

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief medical officer Nadya Lisovoder speaks to Proactive's Thomas Warner after announcing the completion of an in-vitro pre-clinical mechanism of action (MoA) study for the European based bio-pharma company's CimetrA platform. Lisovoder says that the fact MGC "totally understands" CimetrA represents a "very important step" in the development process. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 13, 2023 08:26 AM Eastern Daylight Time

Video
1 ... 123124125126127 ... 248